PDS Biotechnology Corporation — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; filed March 28, 2023. Although the request identifies 2022 Q4, this is an annual filing, and the supplied text does not provide a clear standalone fourth-quarter income statement or cash-flow breakdown.
Business context
PDS Biotechnology is a clinical-stage immunotherapy company with no approved products and no product revenue. Its pipeline is based on Versamune cancer immunotherapies, Versamune combined with PDS0301 (IL-12), and Infectimune infectious-disease vaccines. PDS0101, targeting HPV-associated cancers, is its lead clinical candidate.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $29.4 million | $11.3 million |
| General and administrative expense | $12.2 million | $10.2 million |
| Total operating expenses / operating loss | $41.7 million / $(41.7) million | $21.4 million / $(21.4) million |
| Net loss | $(40.9) million | $(16.9) million |
| Net loss per share, basic and diluted | $(1.43) | $(0.66) |
| Net cash used in operating activities | $(25.7) million | $(12.5) million |
| Cash and cash equivalents at year-end | $73.8 million | $65.2 million |
R&D expense rose 162%, principally reflecting higher project, clinical, personnel, quality and manufacturing costs, and $10.0 million recorded for the PDS0301 license. G&A expense increased 20%. The 2022 net loss also included $0.4 million of net interest expense, compared with modest net interest income in 2021, and a $1.2 million income-tax benefit, down from $4.5 million. No revenue-based margin is meaningful because the company reported no product revenue.
Financing activities provided $34.3 million in 2022, including $24.6 million net proceeds from a venture loan and $9.9 million net from ATM stock sales. Year-end total liabilities were $33.0 million, including $23.0 million of note payable net of debt discount; stockholders’ equity was $44.0 million. The loan bears floating interest at prime plus 5.75% (subject to a 4.00% floor), is secured by company assets other than intellectual property, and includes operating restrictions. Additional $10 million of loans were uncommitted and subject to lender discretion and conditions.
Management estimated available resources would fund operations and R&D into the third quarter of 2024, based on projections available when the financial statements were issued. It also said future capital may be needed; the estimate depends on clinical costs, timelines, financing availability and other assumptions.
Material developments, outlook and risks
- PDS0101 with pembrolizumab: In preliminary VERSATILE-002 data presented in 2022, 7 of 17 evaluable patients had an objective response, including two complete responses; no treatment-related Grade 3 or higher events were reported in the 19-patient safety group. These are interim, small-sample results, not a controlled comparison. The FDA granted Fast Track designation for the combination and provided feedback at an end-of-Phase-2 meeting. The company described plans for a potential registrational program, including a planned amended IND in 2023.
- NCI triple-combination study: Interim investigator-led Phase 2 results for PDS0101, PDS0301 and bintrafusp alfa included a reported 21-month median overall survival in 29 checkpoint-inhibitor-refractory patients and a 63% response rate in the stated optimal-dose subgroup (5 of 8). The filing compares these outcomes with historical results; they are not randomized, head-to-head evidence. Grade 3 treatment-related events were reported in 48% of the broader 50-patient safety group and Grade 4 events in 4%; no Grade 5 events were reported. The FDA held a Type B meeting in February 2023 on a potential registrational study of a related combination using an FDA-approved checkpoint inhibitor.
- Merck KGaA license: The company obtained exclusive worldwide rights to PDS0301 in a December 2022 agreement, paying $5.0 million cash and issuing 378,787 shares valued at $5.0 million. Terms include up to $11 million in development and first-sale milestones, up to $105 million in sales milestones, and a 10% net-sales royalty, subject to specified reductions.
- Other programs: PDS0103 remained in late preclinical development; PDS0102 and infectious-disease candidates were earlier-stage. The company said further development of some programs depended on nondilutive funding and resource allocation. PDS0202 universal-flu and PDS0203 COVID-19 evidence described in the filing is preclinical.
- Principal risks: Continued losses and financing dependence; uncertain clinical and regulatory outcomes; reliance on third-party manufacturers, CROs and clinical sites; patient enrollment and trial delays; competition; intellectual-property protection; and possible dilution or debt restrictions. The company reported no material pending legal proceeding and no material off-balance-sheet arrangements.
Management provided no quantified revenue or earnings guidance. It expects losses and negative operating cash flows to continue while it funds development. The filing describes planned development steps, but timelines and financing are uncertain. The independent auditor gave an unqualified opinion on the financial statements; management reported effective disclosure controls and internal control over financial reporting as of year-end. The auditor was not engaged to opine on internal-control effectiveness.
Most important facts for investors to verify
- Current cash runway and post-year-end cash use, including the reported $4.6 million of net ATM proceeds raised in the first quarter of 2023.
- Whether PDS0101’s preliminary response and safety findings hold with longer follow-up and in a sufficiently powered registrational trial; verify the final FDA-agreed design and enrollment timeline.
- Study denominators, dose groups, follow-up periods and adverse-event figures for the NCI triple-combination results; distinguish interim observations from controlled evidence.
- Actual borrowing outstanding, floating-rate expense, amortization schedule, covenant compliance and availability of the uncommitted loan tranches.
- The full economics and obligations of the PDS0301 license, and whether milestone and royalty commitments are triggered.
- Manufacturing capacity, clinical-trial enrollment progress and the extent to which later-stage programs depend on additional financing.
- Potential source-text inconsistencies: the MD&A refers to an FDA meeting in “October 2023,” while other filing sections place the end-of-Phase-2 meeting in October 2022; confirm the intended date.